vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and WARRIOR MET COAL, INC. (HCC). Click either name above to swap in a different company.
WARRIOR MET COAL, INC. is the larger business by last-quarter revenue ($458.6M vs $284.0M, roughly 1.6× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 15.8%, a 80.6% gap on every dollar of revenue. On growth, WARRIOR MET COAL, INC. posted the faster year-over-year revenue change (52.1% vs 9.4%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 7.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Warrior Met Coal, Inc. (ticker HCC) is a U.S.-headquartered mining enterprise that produces and distributes high-grade metallurgical coal, a key raw material for steel production. It serves steel manufacturers and industrial clients across core markets including North America, Europe, and Asia.
ACAD vs HCC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $458.6M |
| Net Profit | $273.6M | $72.3M |
| Gross Margin | 90.8% | 36.7% |
| Operating Margin | 6.1% | 17.3% |
| Net Margin | 96.3% | 15.8% |
| Revenue YoY | 9.4% | 52.1% |
| Net Profit YoY | 90.3% | — |
| EPS (diluted) | $1.61 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $458.6M | ||
| Q4 25 | $284.0M | $384.0M | ||
| Q3 25 | $278.6M | $328.6M | ||
| Q2 25 | $264.6M | $297.5M | ||
| Q1 25 | $244.3M | $299.9M | ||
| Q4 24 | $259.6M | $297.5M | ||
| Q3 24 | $250.4M | $327.7M | ||
| Q2 24 | $242.0M | $396.5M |
| Q1 26 | — | $72.3M | ||
| Q4 25 | $273.6M | $23.0M | ||
| Q3 25 | $71.8M | $36.6M | ||
| Q2 25 | $26.7M | $5.6M | ||
| Q1 25 | $19.0M | $-8.2M | ||
| Q4 24 | $143.7M | $1.1M | ||
| Q3 24 | $32.8M | $41.8M | ||
| Q2 24 | $33.4M | $70.7M |
| Q1 26 | — | 36.7% | ||
| Q4 25 | 90.8% | 29.5% | ||
| Q3 25 | 92.2% | 27.1% | ||
| Q2 25 | 92.2% | 23.9% | ||
| Q1 25 | 91.7% | 18.1% | ||
| Q4 24 | 91.6% | 23.1% | ||
| Q3 24 | 92.5% | 29.3% | ||
| Q2 24 | 92.5% | 34.1% |
| Q1 26 | — | 17.3% | ||
| Q4 25 | 6.1% | 9.0% | ||
| Q3 25 | 12.8% | 6.3% | ||
| Q2 25 | 12.2% | 2.6% | ||
| Q1 25 | 7.9% | -5.8% | ||
| Q4 24 | 59.1% | -1.4% | ||
| Q3 24 | 12.6% | 11.9% | ||
| Q2 24 | 12.6% | 17.9% |
| Q1 26 | — | 15.8% | ||
| Q4 25 | 96.3% | 6.0% | ||
| Q3 25 | 25.8% | 11.1% | ||
| Q2 25 | 10.1% | 1.9% | ||
| Q1 25 | 7.8% | -2.7% | ||
| Q4 24 | 55.4% | 0.4% | ||
| Q3 24 | 13.1% | 12.7% | ||
| Q2 24 | 13.8% | 17.8% |
| Q1 26 | — | $1.37 | ||
| Q4 25 | $1.61 | $0.43 | ||
| Q3 25 | $0.42 | $0.70 | ||
| Q2 25 | $0.16 | $0.11 | ||
| Q1 25 | $0.11 | $-0.16 | ||
| Q4 24 | $0.86 | $0.02 | ||
| Q3 24 | $0.20 | $0.80 | ||
| Q2 24 | $0.20 | $1.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $233.2M |
| Total DebtLower is stronger | — | $154.4M |
| Stockholders' EquityBook value | $1.2B | — |
| Total Assets | $1.6B | $2.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $233.2M | ||
| Q4 25 | $177.7M | $300.0M | ||
| Q3 25 | $258.0M | $336.3M | ||
| Q2 25 | $253.6M | $383.3M | ||
| Q1 25 | $217.7M | $454.9M | ||
| Q4 24 | $319.6M | $491.5M | ||
| Q3 24 | $155.1M | $583.2M | ||
| Q2 24 | $177.1M | $709.0M |
| Q1 26 | — | $154.4M | ||
| Q4 25 | — | $154.3M | ||
| Q3 25 | — | $154.1M | ||
| Q2 25 | — | $153.9M | ||
| Q1 25 | — | $153.8M | ||
| Q4 24 | — | $153.6M | ||
| Q3 24 | — | $153.5M | ||
| Q2 24 | — | $153.3M |
| Q1 26 | — | — | ||
| Q4 25 | $1.2B | $2.1B | ||
| Q3 25 | $917.3M | $2.1B | ||
| Q2 25 | $822.4M | $2.1B | ||
| Q1 25 | $765.2M | $2.1B | ||
| Q4 24 | $732.8M | $2.1B | ||
| Q3 24 | $577.2M | $2.1B | ||
| Q2 24 | $516.7M | $2.0B |
| Q1 26 | — | $2.8B | ||
| Q4 25 | $1.6B | $2.8B | ||
| Q3 25 | $1.3B | $2.7B | ||
| Q2 25 | $1.2B | $2.6B | ||
| Q1 25 | $1.1B | $2.6B | ||
| Q4 24 | $1.2B | $2.6B | ||
| Q3 24 | $976.9M | $2.6B | ||
| Q2 24 | $914.1M | $2.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.07× | ||
| Q3 25 | — | 0.07× | ||
| Q2 25 | — | 0.07× | ||
| Q1 25 | — | 0.07× | ||
| Q4 24 | — | 0.07× | ||
| Q3 24 | — | 0.07× | ||
| Q2 24 | — | 0.07× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-48.7M | $76.1M | ||
| Q3 25 | $74.3M | $104.7M | ||
| Q2 25 | $64.0M | $37.5M | ||
| Q1 25 | $20.3M | $10.9M | ||
| Q4 24 | $40.4M | $54.2M | ||
| Q3 24 | $63.2M | $62.2M | ||
| Q2 24 | $25.0M | $147.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $73.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $63.2M | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 26.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | -0.18× | 3.31× | ||
| Q3 25 | 1.03× | 2.86× | ||
| Q2 25 | 2.40× | 6.70× | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | 47.68× | ||
| Q3 24 | 1.93× | 1.49× | ||
| Q2 24 | 0.75× | 2.08× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
HCC
| Sales | $448.5M | 98% |
| Other revenues | $10.1M | 2% |
